NEW YORK (Reuters) – A task force advising the U.S. government on Monday recommended against routine use of the prostate-cancer screening test called PSA, or prostate specific antigen, for lack of a discernible health benefit.
Popular Posts:
- FDA approves Zaltrap for metastatic colorectal cancer
- U.S. needs arsenic limits in rice: Consumer Reports
- Roche says skin cancer drug substantially shrinks
- Roche says skin cancer drug substantially shrinks
- Roche says skin cancer drug substantially shrinks
Incoming search terms:
- does obama healcare bill allow rfid chips
- healthcare bill postarte cancer
- mandatory microchips by 2013